Sign In
Buy SNDX
$18.34
-0.0500 (-0.272%)
At Close: Jun 03, 2026
Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes
07:00am, Thursday, 04'th Jun 2026
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (“Syndax”) (NASDAQ: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, has entered
Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data
04:01pm, Tuesday, 02'nd Jun 2026
– Pooled analysis of 24 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who resumed revumenib post-transplant shows favorable outcomes, including a 2-year overall survival rate of 9
Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026
07:00am, Monday, 01'st Jun 2026
NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will host
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
05:01pm, Thursday, 21'st May 2026
– Oral presentation will highlight favorable outcomes observed among 21 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who received revumenib post-transplant –
Syndax Announces Participation in Upcoming Investor Conferences
07:00am, Wednesday, 20'th May 2026
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Me
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition
10:31am, Tuesday, 12'th May 2026
– Abstracts highlight strong revumenib activity across the acute leukemia treatment continuum and multiple genetic subtypes – – New real-world data show compelling outcomes and favorable tolerab
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Wednesday, 06'th May 2026
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on May 1, 202
Syndax Pharmaceuticals, Inc. (SNDX) Q1 2026 Earnings Call Transcript
10:51pm, Thursday, 30'th Apr 2026
Syndax Pharmaceuticals, Inc. (SNDX) Q1 2026 Earnings Call Transcript
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates
06:30pm, Thursday, 30'th Apr 2026
Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to a loss of $0.98 per share a year ago.
Syndax Reports First Quarter 2026 Financial Results and Provides Business Update
04:01pm, Thursday, 30'th Apr 2026
– Total revenue of $64.9 million in 1Q26, a 224% year-over-year increase – – Revuforj ® (revumenib) net revenue of $48.9 million in 1Q26, highlighting leadership in menin inhibition and increas
Nuvation Bio Inc. (NUVB) Reports Next Week: Wall Street Expects Earnings Growth
11:05am, Monday, 27'th Apr 2026
Nuvation Bio (NUVB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026
07:00am, Friday, 24'th Apr 2026
NEW YORK, April 24, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will rep
SG Americas Securities LLC Has $2.72 Million Stock Position in Syndax Pharmaceuticals, Inc. $SNDX
05:01am, Saturday, 04'th Apr 2026
SG Americas Securities LLC raised its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) by 184.5% during the undefined quarter, according to its most recent disclosure with the Securities and Ex
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Friday, 03'rd Apr 2026
NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on April 1,
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Rating of “Moderate Buy” by Brokerages
02:40am, Monday, 23'rd Mar 2026
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the twelve brokerages that are covering the firm, MarketBeat reports. One research
